Skip to main
ROIV

ROIV Stock Forecast & Price Target

ROIV Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 60%
Buy 30%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Roivant Sciences is a commercial-stage biopharmaceutical company that has a promising future due to its diverse portfolio of drug candidates and business model that both support growth potential. The company has experienced strong financial performance, with an increase in revenue and decrease in expenses in its most recent quarter. Additionally, Roivant's management team appears confident in the potential of its drug candidates, as evidenced by the successful enrollment in its Phase 2 study and plans for commercial launches and proof-of-concept readouts. With strong cash reserves and multiple catalysts on the horizon, Roivant Sciences is well-positioned for continued success in the biopharmaceutical industry.

Bears say

Roivant Sciences is facing significant challenges with its drug candidates Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others still in various stages of development and a projected launch date of September 2026 for their most advanced drug dermatomyositis (DM). While the recent success of IMVT-1402 in D2TRA may have improved sentiment towards the company, it is still too early to accurately predict future success. Additionally, the potential combination strategy of mosliciguat and treprostinil in PH-ILD may face difficulties in the current competitive market.

ROIV has been analyzed by 10 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 30% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Roivant Sciences Ltd (ROIV) Forecast

Analysts have given ROIV a Buy based on their latest research and market trends.

According to 10 analysts, ROIV has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Roivant Sciences Ltd (ROIV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.